Caris Diagnostics' Test Supports Effective Personalized Treatment
Good news on the personalized medicine frontier. Clinical study results released at the 100th Annual Meeting of the American Association for Cancer Research in Denver, CO, indicated that the molecular profiling of patients through the Caris Diagnostics’ Target Now molecular profiling analysis identifies individual genetic profiles that often drive more informed and effective personalized treatment options.  The findings provide early validation for the application of therapy selection through molecular profiling, resulting in improved patient care and enhanced outcomes. The research trial was funded through the Scottsdale Healthcare Foundation with a grant from the The Stardust Foundation and led by Dr. Daniel Von Hoff M.D., Senior Investigator and Chief Scientific Officer of TGen Clinical Research Services at Scottsdale Healthcare and consultant for the Tissue Banking and Analysis Center, a research subsidiary of Caris Dx. Von Hoff and his clinical colleagues utilized Target Now to profile patients with late-stage cancer.  All patients in the study had previously experienced growth of their tumors while undergoing anywhere from two to thirteen previous cancer treatments, including standard guideline chemotherapies.